Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

845 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.
Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, van Leerdam ME, van den Heuvel M, Blank CU, van Dieren J, Haanen JBAG. Geukes Foppen MH, et al. Among authors: van wilpe s, van thienen jv, van leerdam me, van dieren j, van den heuvel m. ESMO Open. 2018 Jan 13;3(1):e000278. doi: 10.1136/esmoopen-2017-000278. eCollection 2018. ESMO Open. 2018. PMID: 29387476 Free PMC article. Review.
Polyfunctional tumor-reactive T cells are effectively expanded from non-small cell lung cancers, and correlate with an immune-engaged T cell profile.
De Groot R, Van Loenen MM, Guislain A, Nicolet BP, Freen-Van Heeren JJ, Verhagen OJHM, Van Den Heuvel MM, De Jong J, Burger P, Van Der Schoot CE, Spaapen RM, Amsen D, Haanen JBAG, Monkhorst K, Hartemink KJ, Wolkers MC. De Groot R, et al. Among authors: van den heuvel mm, van der schoot ce, van loenen mm. Oncoimmunology. 2019 Aug 15;8(11):e1648170. doi: 10.1080/2162402X.2019.1648170. eCollection 2019. Oncoimmunology. 2019. PMID: 31646094 Free PMC article.
PD-1T TILs as a Predictive Biomarker for Clinical Benefit to PD-1 Blockade in Patients with Advanced NSCLC.
Hummelink K, van der Noort V, Muller M, Schouten RD, Lalezari F, Peters D, Theelen WSME, Koelzer VH, Mertz KD, Zippelius A, van den Heuvel MM, Broeks A, Haanen JBAG, Schumacher TN, Meijer GA, Smit EF, Monkhorst K, Thommen DS. Hummelink K, et al. Among authors: van den heuvel mm, van der noort v. Clin Cancer Res. 2022 Nov 14;28(22):4893-4906. doi: 10.1158/1078-0432.CCR-22-0992. Clin Cancer Res. 2022. PMID: 35852792 Free PMC article.
Mechanisms of Immune Checkpoint Inhibitor-Mediated Colitis.
Westdorp H, Sweep MWD, Gorris MAJ, Hoentjen F, Boers-Sonderen MJ, van der Post RS, van den Heuvel MM, Piet B, Boleij A, Bloemendal HJ, de Vries IJM. Westdorp H, et al. Among authors: van den heuvel mm, van der post rs. Front Immunol. 2021 Oct 29;12:768957. doi: 10.3389/fimmu.2021.768957. eCollection 2021. Front Immunol. 2021. PMID: 34777387 Free PMC article. Review.
Diagnostic validation and interpretation of longitudinal circulating biomarkers using a biomarker response characteristic plot.
Moritz R, Muller M, Korse CM, van den Broek D, Baas P, van den Noort V, Ten Hoeve JJ, van den Heuvel MM, van Rossum HH. Moritz R, et al. Among authors: van den noort v, van den broek d, van den heuvel mm, van rossum hh. Clin Chim Acta. 2018 Dec;487:6-14. doi: 10.1016/j.cca.2018.09.015. Epub 2018 Sep 8. Clin Chim Acta. 2018. PMID: 30201371
Study protocols of three parallel phase 1 trials combining radical radiotherapy with the PARP inhibitor olaparib.
de Haan R, van Werkhoven E, van den Heuvel MM, Peulen HMU, Sonke GS, Elkhuizen P, van den Brekel MWM, Tesselaar MET, Vens C, Schellens JHM, van Triest B, Verheij M. de Haan R, et al. Among authors: van werkhoven e, van den heuvel mm, van den brekel mwm, van triest b. BMC Cancer. 2019 Sep 10;19(1):901. doi: 10.1186/s12885-019-6121-3. BMC Cancer. 2019. PMID: 31500595 Free PMC article.
845 results